Mirae Asset Global Investments
ESPR

Mirae Asset Global Investments’s Esperion Therapeutics ESPR Stock Holding History

Mirae Asset Global Investments’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.2K Buy
12,469
+852
+7% +$2.7K ﹤0.01% 1361
2025
Q4 		$43K Buy
11,617
+3,822
+49% +$12.3K ﹤0.01% 1430
2025
Q3 		$20.7K Buy
7,795
+139
+2% +$269 ﹤0.01% 1487
2025
Q2 		$7.54K Buy
7,656
+1,260
+20% +$1.26K ﹤0.01% 1521
2025
Q1 		$9.59K Sell
6,396
-170
-3% -$313 ﹤0.01% 1474
2024
Q4 		$15K Buy
+6,566
New +$15.3K ﹤0.01% 1461
2023
Q1 		– Sell
-26,267
Closed -$164K – 2550
2022
Q4 		$164K Buy
26,267
+204
+0.8% +$1.46K ﹤0.01% 2345
2022
Q3 		$174K Buy
26,063
+8,044
+45% +$55.2K ﹤0.01% 2385
2022
Q2 		$114K Buy
+18,019
New +$102K ﹤0.01% 2283
2015
Q4 		– Sell
-47,500
Closed -$1.12M – 463
2015
Q3 		$1.12M Buy
47,500
+25,480
+116% +$1.6M 0.05% 279
2015
Q2 		$1.8M Buy
22,020
+6,590
+43% +$645K 0.06% 224
2015
Q1 		$1.43M Buy
+15,430
New +$996K 0.05% 251

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mirae Asset Global Investments's ESPR Position: Q1 2026 in Review

Mirae Asset Global Investments increased its Esperion Therapeutics (ESPR) stake by 7.3% in Q1 2026, buying an estimated $2.7K and bringing the position to 12,469 shares worth $34.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1361.

Mirae Asset Global Investments first reported a position in ESPR in Q1 2015 and has held it in 12 quarters since. The position peaked at $1.8M in Q2 2015. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Mirae Asset Global Investments held 12,469 shares of Esperion Therapeutics worth $34.2K as of Q1 2026.
  • Mirae Asset Global Investments bought 852 Esperion Therapeutics shares in Q1 2026, an estimated $2.7K.
  • Esperion Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q1 2026, its #1361 holding.
  • Mirae Asset Global Investments first reported a position in Esperion Therapeutics in Q1 2015 and has held it in 12 quarters since.
  • Mirae Asset Global Investments's Esperion Therapeutics position peaked at $1.8M in Q2 2015.
  • 205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Mirae Asset Global Investments's 13F filing for Q1 2026, filed 4 May 2026.